Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439757 | 0.98 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1RAB9ALMNATDP1 | |
| SCHEMBL19926076 | 0.90 | TSHR (0.41) | L3MBTL1ALDH1A1RAB9ALMNATDP1 | |
| SCHEMBL6677700 | 0.86 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL5572124 | 0.84 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL11125921 | 0.83 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL27295498 | 0.82 | SLC6A1 (0.38) | L3MBTL1ALDH1A1RAB9ATDP1EPHX1 | |
| SCHEMBL17928311 | 0.80 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL29136168 | 0.80 | MEN1 (0.48) | L3MBTL1ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL1401342 | 0.80 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1TDP1KMT2A | |
| SCHEMBL25311355 | 0.79 | TDP1 (0.50) | L3MBTL1ALDH1A1LMNATDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221003-A1 | CONSUMER PRODUCTS HAVING VARYING ODOR PATTERNS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-09-11 | — | — | US | claimed |
| US-20080207481-A1 | CONSUMER PRODUCTS HAVING VARYING ODORS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-08-28 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-9719058-B2 | Fragrant oil encapsulation | PAPIERFABRIK AUGUST KOEHLER SE (DE) | 2017-08-01 | — | — | US | disclosed |
| CN-103145553-B | Synthesis and application of 2, 3-alkyl substituted diester succinate | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2016-06-01 | — | — | CN | disclosed |
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| US-20150210965-A1 | FRAGRANT OIL ENCAPSULATION | SYMRISE AG (DE) | 2015-07-30 | — | — | US | disclosed |
| CN-103145553-A | Synthesis and application of 2, 3-alkyl substituted diester succinate | UNIV DALIAN TECH | 2013-06-12 | — | — | CN | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20120308486-A1 | Fragrance and/or flavoring compositions containing dioxolanes | SYMRISE AG (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | L3MBTL1 4192/4885ALDH1A1 804/4885RAB9A 4302/4885 |
| US-20120308486-A1 | Fragrance and/or flavoring compositions containing dioxolanes | FDFT1, DECR1, DOHH | L3MBTL1 4861/4885ALDH1A1 69/4885RAB9A 4531/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | L3MBTL1 2182/4885ALDH1A1 570/4885RAB9A 2417/4885 |
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | SI, ALPI, GAA | L3MBTL1 214/4885ALDH1A1 273/4885RAB9A 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.